The Food and Drug Administration (FDA) decision to lift restrictions on the abortion pill mifepristone — paving the way for women to obtain the pill by mail and self-perform abortions as early as 10 weeks of gestation without an in-person clinic visit — has drawn new criticism from pro-life advocates.